Cargando…
Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages
Patient selection for PI3K-targeted solid cancer treatment was based on the PIK3CA/PTEN mutational status. However, it is increasingly clear that this is not a good predictor of the response of breast cancer cells to the anti-proliferative effect of PI3K inhibitors, indicating that isoform(s) other...
Autores principales: | Goulielmaki, Evangelia, Bermudez-Brito, Miriam, Andreou, Margarita, Tzenaki, Niki, Tzardi, Maria, de Bree, Eelco, Tsentelierou, Eleftheria, Makrigiannakis, Antonis, Papakonstanti, Evangelia A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5992183/ https://www.ncbi.nlm.nih.gov/pubmed/29880805 http://dx.doi.org/10.1038/s41419-018-0717-4 |
Ejemplares similares
-
p110δ PI3 kinase pathway: emerging roles in cancer
por: Tzenaki, Niki, et al.
Publicado: (2013) -
Focus on PTEN Regulation
por: Bermúdez Brito, Miriam, et al.
Publicado: (2015) -
Differential Expression of CRH, UCN, CRHR1 and CRHR2 in Eutopic and Ectopic Endometrium of Women with Endometriosis
por: Vergetaki, Aikaterini, et al.
Publicado: (2013) -
Galectin-1 Overexpression in Endometriosis and Its Regulation by Neuropeptides (CRH, UCN) Indicating Its Important Role in Reproduction and Inflammation
por: Vergetaki, Aikaterini, et al.
Publicado: (2014) -
Control of Axonal Growth and Regeneration of Sensory Neurons by the p110δ PI 3-Kinase
por: Eickholt, Britta J., et al.
Publicado: (2007)